CGRP Forum is made possible thanks to support from AbbVie, Lilly, Organon and Pfizer, all of whom have no influence or control over editorial content. More information is available here »
21-24 June 2025
Optimal migraine control or migraine freedom, as defined in the International Headache Society goals for migraine prevention published earlier this year, are achieved in real-world settings with CGRP mAbs in approximately 40% of individuals with a high migraine burden. This finding from a European prospective, real-world study, including adults with migraine treated with CGRP mAbs …
Read more »CGRP mAb therapy is proving as effective in Ukraine as around the world, but patients are experiencing considerable challenges in accessing treatment. Single centre data on 47 patients treated with fremanezumab since 2021, reported by Drs Nayaliya and Myroslav Bozhenko at Danylo Halytsky Lviv National Medical University, have shown that 28 (59.6%) patients achieved a …
Read more »GLP-1 receptor agonists used to treat diabetes may also have beneficial effects for people with migraine through an indirect effect on CGRP release. Results of a small study in 26 adults with obesity and chronic migraine showed that the GLP-1 agonist, liraglutide, reduced mean monthly headache days from 20.04±6.38 to 8.81±6.01 (mean difference 11.23, p<0.001), …
Read more »CGRP mAb therapy treatment was effective in patients diagnosed with chronic migraine (CM) refractory to onabotulinumtoxinA (BoNT-A), with high levels of compliance and safety after six months of treatment. This was the finding from the Re-MATE (Real-Migraine Antibodies Treatments Evidence) observational, retrospective study in 70 patients with CM previously treated for 12.7+2.4 months with BoNT-A. …
Read more »CGRP mAb treatment is more effective in reducing migraine frequency outside the perimenstrual period (non-PMD) than during the PMD, according to results of a retrospective cohort analysis of 29 women, 11 of whom had episodic and 18 of whom had chronic migraine. The women met the ICHD-3 criteria for either pure menstrual migraine or menstrually …
Read more »Further data from the real world, prospective, observational CONFIDENCE study continue to support the consistency of response to rimegepant. Of the 118 patients with episodic migraine who had at least three rimegepant-treated migraines, 62.7% achieved meaningful pain relief within two hours in at least two of their first three attacks, and 83.9% achieved meaningful pain relief …
Read more »
This program is funded in part via an independent educational grant from AbbVie.
Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
